NeoPharm is a publicly traded biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. NeoPharm has built its drug development program around two proprietary technology platforms: a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid® liposomal drug delivery system. The company has advanced five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis, or IPF, and asthma. NeoPharm's stock is traded over-the-counter (OTC) under the stock symbol NEOL.PK. NeoPharm's corporate office and research and development facility is located in Lake Bluff, Illinois. NeoPharm’s new management team, enlisted in March of 2007, has undertaken a concentrated plan.